REGN News and Press, Regeneron Pharmaceuticals Inc. From 02/05/26

2026-02-05 15:07:58 ET Image source: The Motley Fool. Tuesday, April 29, 2025 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-05 15:03:49 ET Image source: The Motley Fool. Friday, August 1, 2025 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-05 15:00:31 ET Image source: The Motley Fool. Tuesday, Feb. 4, 2025 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-05 14:59:40 ET Image source: The Motley Fool. Oct. 31, 2024 at 8:30 a.m. ET Need a quote from a Motley Fool analyst? Email pr@fool.com Continue reading

2026-02-02 08:15:52 ET In 2025, Insmed ( INSM ) was the envy of the biotech sector. The stock more than doubled from January through December 2025, substantially outpacing both biotech and the broader market. Investors discovered the company following the approval of Brinsupri...

2026-02-02 08:11:25 ET More on Regeneron Pharmaceuticals Regeneron: Expect Double-Digit Growth In 2026 Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation Regen...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026. These ...

2026-02-01 09:05:00 ET On February 6, 2026, the Bureau of Labor Statistics will report non-farm payrolls for January. In last month’s release of November job data, investors had five things to consider . The ADP report suggested job cuts in November. More specifically, monthl...

2026-01-31 08:33:47 ET Regeneron ( REGN ) closed slightly lower yesterday after reporting Q4 2025 results that were slightly better than the market consensus, and providing expense guidance for 2026. However, there were no major surprises, as the company pre-announced Eylea ...

2026-01-30 16:04:35 ET from Raymond James issued a price target of $870.00 for REGN on 2026-01-30 20:32:51. The adjusted price target was set to $870.00. At the time of the announcement, REGN was trading at $741.45. The overall price target consensus is at $821.22 with h...